Introduction
Urothelial carcinoma of the bladder (UBC) is the fourth most common malignancy in men and the eighth most common cause of male cancer deaths in the USA [1] . Pathological staging and grading continue to be the most powerful criteria in relation to therapy of choice and prognosis of the disease. Whereas molecular diagnostics has become an integral part of routine clinical management for patients with breast, colon and lung cancer, biomarkers play only a minor role in current management strategies for UBC. Therefore, there is still a need for prognostic molecular markers that can help clinicians select patients in need of early surgical and/or neoadjuvant management.
The prognostic significance of aquaporin (AQP) water channel expression in UBC has not been investigated in larger patient cohorts to date. AQPs are a family of transmembrane channel-forming proteins that selectively allow water and other small, uncharged molecules to pass across cell membranes in response to osmotic or pressure gradients.
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We have previously demonstrated that normal, i.e. non-diseased, human urothelium expresses several AQPs, suggesting a potential role in water and urea transport across the urothelial layer [2] . Predominant expression of AQP3 is supportive of the hypothesis that the urothelium may be able to modify volume and final composition of the urine [3] . Apart from its crucial significance in human physiology, there is strong presumptive evidence that AQPs play a role in carcinogenesis, such as in tumour angiogenesis and cell migration [4] .
On the basis of our findings in normal human urothelium, we have previously investigated the expression and potential significance of AQPs in UBC and showed that there is a significant correlation between AQP3 protein expression and tumour progression, with AQP3 expression being reduced or lost in tumours of higher grade and stage. We concluded that AQPs may play a role in the progression of UBC and, in particular, that this could be of prognostic value [5] . In support of this, we have recently demonstrated that loss of AQP3 protein expression was an independent marker associated with worse progression-free survival in patients with pT1 UBC, a finding that was confirmed by multivariate Cox regression analysis [6] .
To date, the clinical significance of AQP3 protein expression in muscle-invasive bladder cancer (MIBC) remains unexplored. The aim of the present study was to investigate the prognostic value of AQP3 in terms of progression and survival of patients diagnosed with MIBC and to discuss the potential usefulness of the marker with regard to the design of therapeutic strategies.
Materials and methods
Patients with MIBC (pT2-T4) having undergone radical cystectomy and pelvic lymph node dissection in our department between 2001 and 2006 were included in the present study. Cases in whom the histological evaluation of the cystectomy specimen did not confirm MIBC, patients with distant metastases at initial diagnosis and those who received neoadjuvant chemotherapy prior to surgery were not included in the study.
Adjuvant chemotherapy (CTx) was recommended to patients with lymph node involvement (pN+). Urooncologic follow-up was performed in all patients.
Clinicopathological data and follow-up were assessed in all patients.
Immunohistochemistry
Cystectomy specimens were processed, fixed in 10 % formalin, dehydrated and embedded in paraffin wax. Dewaxed 4-μm tissue sections were subjected to antigen retrieval by boiling for 10 min in tris-ethylenediaminetetraacetic acid before labelling with titrated primary antibody (polyclonal anti-AQP3, host: rabbit, antigen: human AQP3, dilution 1:2000, Abcam, USA) for 16 h at 4 °C, as described [5] . Positive control tissues of normal human urothelium known to express the antigen and negative controls in which the primary antibody was omitted were included in all experiments. All slides were examined in a blind fashion by two of the authors (P.R. and A.H.) using a Primo Star™ microscope (Carl Zeiss Microimaging, Jena, Germany).
Assessment of AQP3 protein expression
Labelled photomicrographs were ranked according to immunohistochemical patterns relating to the expression and distribution of AQP3 within the tumour. The ranking criteria used to grade the antigen expression were as follows: 0 no expression 1 cytoplasmatic expression 2 weak cell membrane-associated expression 3 intense expression restricted to the cell borders Each sample was assigned a numerical value according to its rank.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics, version 21.0 (SPSS Inc, Chicago, IL). Several patient characteristics and clinicopathological parameters were evaluated in relation to the AQP3 protein expression status of the patients using Fisher's exact test. Progression-free, cancer-specific and overall survival rates depending on AQP3 expression were assessed by Kaplan-Meier analysis. Multivariate Cox regression analysis was performed to explore the prognostic value of AQP3 expression and clinicopathological parameters in terms of progression, cancer-specific and overall survival. p values <0.05 were considered statistically significant.
Results

Patient characteristics
One hundred patients were included in the study. Patient characteristics, clinical and histopathological data are summarized in Fig. 1 .
Oncological outcome
Median follow-up was 33 (11-123) months. In the course of follow-up, 10 % of patients were diagnosed with local tumour recurrence. Systemic progression, i.e. distant metastases, occurred in 30 % of patients. At the end of the follow-up period, a total of 40 % of patients were alive, whilst 60 % had died (38 % cancer-specific mortality and 22 % from other causes than UBC).
Expression of AQP3
Overall, 65 % of tumours were classified as AQP3 negative (no expression, rank 0). Expression of AQP3 was shown to be present in 35 % of all tumour specimens. Intense membranous expression, as seen in normal human urothelium, was found in 23 % (rank 3), whereas weak labelling (rank 1 and rank 2) was present in 12 % of tumours. Interobserver variability was 6 %. These cases were re-evaluated, and the most appropriate rank was agreed upon. Representative immunohistochemistry findings are shown in Fig. 1 .
Having primarily classified the tumours into AQP3 positive and AQP3 negative, the proportion of AQP3-positive tumour areas relative to the whole tumour specimen was subsequently examined, to provide an idea of AQP3 expression heterogeneity. Overall, 20 % of specimens exhibited AQP3 positivity in more than 75 % of the total area of the tumour, whereas expression between 26-75 and <25 % of the tumour was observed 49 and 21 %, respectively. However, further stratification of the cohort according to AQP3 expression heterogeneity did not show relevant differences in survival analysis (results not shown).
In multivariate regression analysis, loss of or reduced AQP3 expression (rank 0-2 vs. 3) was shown to be 
Kaplan-Meier analysis of AQP3 expression in relation to progression-free and cancer-specific survival
Intense, cell membrane-associated AQP3 expression (rank 3) in the cystectomy specimen was associated with a statistically significantly improved 5-year progression-free survival (PFS 75 vs. 19 %, p = 0.043) and cancer-specific survival (CSS 75 vs. 18 %, p = 0.030, see Fig. 1 ) compared with loss of or reduced/abnormal expression (ranks 0, 1 and 2). Despite better overall survival (OS) in patients with intense AQP3 expression (rank 3), the difference did not reach statistical significance (51 vs. 11 %, p = 0.070).
Multivariate Cox regression analysis of the AQP3 expression status and clinicopathological parameters in relation to PFS, CSS and OS
Multivariate Cox regression analysis revealed lymph node (LN) involvement, positive surgical margins and AQP3 expression status to be independent predictors of PFS. LN involvement and AQP3 expression were found to be independent predictors of CSS. Moreover, tumour stage, LN involvement and AQP3 expression status were independent predictors for OS. Results are shown in Table 1 .
Discussion
In the past two decades, a plethora of urothelial carcinoma-associated biomarkers have been identified, including growth factors and their cognate receptors, oncogenes, oncoproteins, tumour suppressor genes, hormone receptors, proliferation and apoptosis markers, and cell adhesion molecules [7] . However, the diagnosis and therapeutic management of patients with bladder cancer continue to be based primarily on conventional clinical and pathological tumour staging and grading.
Despite efforts in establishing tissue biomarkers that may assist urological surgeons in selecting patients in need for early radical surgery and (neo-)adjuvant chemotherapy, the major findings in this field have had little clinical and translational impact so far [7, 8] . To date, lymph node status (pN±) is the most widely accepted clinical predictor of progression-free and cancer-specific survival in patients with MIBC. Hautmann et al. provided compelling data of a large cohort of 1100 patients with MIBC having undergone radical Cx without (neo-)adjuvant chemotherapy. Involvement of only a single lymph node (pN1) was associated with cancer-specific death in over 80 % of patients. None of the patients with pN2/3 survived. The authors suggested that adjuvant CTx should be recommended to patients with histologically proven lymph node involvement. They hypothesized that all patients with MIBC potentially benefit from neoadjuvant CTx [9] . However, Burger et al. [10] only recently presented the results of a survey revealing strong misgivings against neoadjuvant CTx amongst European urologists, presumably due to the lack of clearly defined parameters or markers that help select patients who could benefit from the treatment.
We have previously demonstrated that several AQPs are expressed both in well-established urothelial cancer cell lines and in human bladder carcinoma specimens. Our results indicated that there is a correlation between AQP3 protein expression and tumour stage and grade, with APQ3 expression being reduced or lost in tumours of higher grade and stage. Previous investigations into the significance of AQPs in non-urological tumours have almost invariably demonstrated over-expression of AQP3, and it has been hypothesized that AQP3 may be a promising drug target in the treatment of various epithelial tumours [11, 12] . The contrasting expression pattern of AQP3 between UBC and carcinoma types of non-urothelial origin is striking and may be explained by the hypothesis that in human urothelium, expression and function of AQP3 are associated with the phenotype (proliferative or differentiated) of the cells. Thus, it is conceivable that loss of differentiation may be paralleled by loss of AQP3 expression in tumour cells. Moreover, it is tempting to speculate that loss of AQP3 in UBC may be associated with resistance to apoptotic stimuli, as previously shown for AQP 8 and 9 in hepatocellular carcinoma [13] . Based on these findings, we concluded that AQPs may play a role in the progression of UBC and, in particular, that this could be of prognostic value [5] .
In support of this, we have provided strong presumptive evidence that loss of AQP3 protein expression is associated with worse progression-free survival in patients with pT1G2/G3 carcinomas and we hypothesized that this could also apply to muscle-invasive tumours [6] . This hypothesis seems to be confirmed by the results of the present study.
Intense, cell membrane-restricted AQP3 expression in the cystectomy specimen was associated with both a statistically significantly better 5-year progression-free and cancer-specific survival compared with loss of or reduced and abnormal expression, respectively. Moreover, expression of AQP3 and lymph node involvement were shown to be independent predictors of progression-free, cancer-specific and overall survival in multivariate Cox regression analysis. It is noteworthy in this context that the AQP3 expression status was shown to be independent of clinicopathological parameters such as pathological stage and lymph node involvement. Collectively, our previous and current findings suggest that loss of AQP3 expression may be implicated in a molecular program associated with loss of differentiation, progression to muscle-invasive disease and, ultimately, with mechanisms resulting in metastatic spread, such as lymphovascular invasion and resistance to apoptotic stimuli. Future studies, using our relevant in vitro models, will aim to address these aspects in order to understand the importance of loss of AQP3 expression in UBC and its underlying molecular mechanisms.
In relation to the clinical significance of our findings, we propose that the immunohistochemical assessment of AQP3 in UBC specimens may constitute a clinically relevant supplementary parameter that could, alongside conventional grading and staging, be implemented in future diagnostic and clinical management strategies. Assuming that AQP3 is an independent marker of disease progression, its expression status in the primary transurethral resection specimen could serve as a novel marker that enables urological surgeons to select candidates for early cystectomy (AQP3-negative pT1G3 tumours) versus patients who may benefit from conservative treatment (AQP3-positive tumours). Similarly, loss of AQP3 in muscle-invasive UC of the bladder could serve as a criterion for the selection of patients who are candidates for neoadjuvant chemotherapy prior to Cx.
Nevertheless, the strength of the conclusions from our results may be limited, as we performed a retrospective, single-centre study on a relatively limited number of Cx specimens. Selection bias is likely and has to be considered in the interpretation of the results. Moreover, the large confidence intervals found in multivariate analysis indicate restricted statistical power of the study. Considering the low proportion (23 %) of cases with intense AQP3 expression and the low mortality in this group, 100 specimens seem to be low for a reliable multivariate analysis.
A prospective, appropriately powered, multi-institutional centre study comprising a large number of patients would be required to draw more clinically relevant conclusions from our preliminary observations. Of note also, UBC is well known for its extraordinary tumour heterogeneity reflected by diverse morphological manifestations and various molecular alterations associated with these different tumour phenotypes. Hence, a single marker such as AQP3 is unlikely to be adequate to sufficiently characterize the progression risk and probability of recurrence. Clinical nomograms combining the results from selected biomarkers as well as clinicopathological parameters need to be established to increase the accuracy of clinical predictions. Despite these limitations, the findings of the present study are strongly supportive of the potential significance of AQP3 expression screening in MIBC and provide a platform for further investigations into the biological and clinical relevance of AQP3 in UBC.
Conclusions
Biomarkers that prospectively evaluate tumour aggressiveness, probability of recurrence, progression risk and overall prognosis would improve the care and prognosis of patients with bladder cancer. The present study provides prima facie evidence that the expression of AQP3 by the tumours is an independent predictor of progression-free, cancer-specific and overall survival in patients with muscle-invasive bladder cancer. Integration of AQP3 with conventional clinical and pathologic staging may refine clinical decision-making for the selection of candidates benefiting from (neo-)adjuvant chemotherapy.
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